

# Outperform

( Maintained )

Pharmaceutical

## Yichang Hec Changjiang Pharmaceutical (1558.HK)

Register over-expected earnings performance for 2017

02/09/2018

Target Price: HKD 50.21

### Key Data

Feb. 05, 2018

Closing Price (HKD)	39.50
Total Shares (Mn)	452.02
Shares Outstanding (Mn)	225.82
Market Cap(HKD/Mn)	17854.79
Market Float(HKD/Mn)	8919.89
Net Assets (CNY/Mn)	2643.40
Total Assets (CNY/Mn)	3491.09
BVPS (CNY)	5.85

### Revenue Breakdown (CNY, Mn)

Jun. 30, 2017

Operating Revenue	700.00	
Revenue by Product:	700.00	
1.Anti-Virus Products	600.00	85.71%
2.Cardiovascular Drugs	100.00	14.29%
3.Endocrine and Metabolic Diseases Therapeutic Products	0.00	0.00%
4.Other Products	0.00	0.00%

### Analyst

#### ZHANG Yidong

zhangyidong@xyzq.com  
SFC: BIS749  
SAC: S0190510110012

#### XU Jiayi

xujiayi@xyzq.com.cn  
SAC: S0190513080003

### Assistant Analyst

#### HUANG Hanyang

huanghanyang@xyzq.com.cn  
SAC: S0190116090107

### Key Financial Indicators

FY	2016A	2017E	2018E	2019E
Revenue (Mn/CNY)	942	1501	1883	2307
YoY (%)	35.9%	59.4%	25.5%	22.5%
Net Profit (Mn/CNY)	381	658	826	1003
YoY (%)	43.2%	72.9%	25.5%	21.5%
Gross Margin (%)	77.2%	83.4%	84.0%	84.1%
Net Profit Margin (%)	40.4%	43.8%	43.9%	43.5%
ROE (%)	15.5%	22.4%	23.5%	23.8%
EPS (CNY)	0.84	1.46	1.83	2.22
OCFPS (CNY)	37.7	21.8	17.4	14.3

### Company Profile

Yichang Hec Changjiang Pharmaceutical (the Company, abbreviated as HEC later) is a PRC pharmaceutical manufacturing company that focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The Company currently manufactures, markets and sells a total of 33 pharmaceutical products in the PRC. The Company also manufactures 11 types of APIs, most of which are manufactured for self-use. (Source: Wind)

### Comments

#### HEC reported significant earnings growth for H217.

Company's net profit attributable to shareholders shall increase by no less than 70% for whole 2017. Given the 40.4% profit growth of H117, we expect company's profit growth to exceed 110% for the second half of 2017. We believe the booming earnings growth mainly attributed to three factors: 1) the influenza outbreak in H217 boosted sales of its main product, Kewei (Oseltamivir Phosphate Granules); 2) more sales staff were recruited and the efficiency of promotion activities kept improving; 3) economies of scale and falling costs of raw materials drove up company's gross margin.

#### HEC Pharmaceutical's core product, Kewei, posted surging sales.

We attribute HEC's explosive earnings growth of 2017 to surging sales of Kewei. The annual sales growth may clock in higher than 70% for 2017. Moderate growth in H117 was due to structural reform of sales team and company quitting bid in several provinces.

The influenza outbreak of 2017 became much more severe in H217, fueling surging demand for Kewei (since Kewei was the main chemical drug for treatment). At the same time, fallout of company's sales team reform mitigated gradually and company's sales team continued expanding. The two factors brought company's sales volume back to a fast upward track in H217.

Weaving distribution network across China is gradually gaining HEC access to markets other than Guangdong Province and building new headroom for Kewei. Considering that the current flu may last until H118, and that company's nationwide distribution channel shall bring new momentum, we expect the sales of *Kewei-series* to grow by over 25% in 2018, and by over 20% in 2019

### Earnings forecast and investment grading

The company is developing in line with our expectation that stated in our in-depth report 'The quickly growing poster-boy in Influenza-Antiviral-Drug industry'. Its prime product, Oseltamivir Phosphate Granules (Kewei), as a prevailed chemical drug used to treat influenza, had achieved rapid growth in 2017 (we expect the revenue it contributed to notch an annual growth of over 70%) and is expected

to report over 25% growth for 2018 and a growth of over 20% for 2019.

Company's research and development of other drugs are proceeding steadily at the same time: core products under research, such as the full series of insulin and *Yimitasvir-Phosphate*, are expected to become the company's new growth driver after their debut. The strong R&D capability of the conglomerate that HEC belongs to paves broad way for the company's future development.

Given such, we revise up company's estimated sales revenue of year 2017/2018/2019 to CNY 146mn/183mn/222mn, which implies a P/E ratio of 21.8x/17.4x/14.3x respectively for the three years (calculation is based on closing price of Feb. 05, 2018). We also revise up company's target price to HKD 50.21 and maintain 'Outperform' rating for the company.

**Potential risks:** the sales of *Kewei* may fail to meet expectation; influenza morbidity may be volatile; products under research may be promoted to market later than expected.

## Introduction of Share Investment Rating

### Industry Investment Rating

When measuring the difference between the markup of the industry index and that of the market's benchmarks (Shanghai Composite Index/Shenzhen Component Index) within twelve months after the release of the report, we define the terms as follows:

- **Overweight:** Industry performs better than that of the whole market;
- **Neutral:** Industry performs about the same as that of the whole market;
- **Underweight:** Industry performs worse than that of the whole market

### Company Investment Rating

When measuring the difference between the markup of the company stock price and that of the market's benchmarks (Shanghai Composite Index/Shenzhen Component Index) within twelve months after the release of this report, we define the terms as follows:

- **Buy:** With a markup more than 15% better than that of the market;
- **Outperform:** With a markup 5% to 15% better than that of the market;
- **Neutral:** With a markup less than 5% better or worse than that of the market;
- **Underperform:** With a markup more than 5% worse than that of the market.

### Information Disclosure

The Industrial Securities Co., Ltd. fulfills its duty of disclosure within its sphere of knowledge. The clients may visit the column of Insider Trading Prevention and Control at [www.xyzq.com.cn](http://www.xyzq.com.cn) for the arrangement of the quiet period and the affiliates' shareholdings.

### Analyst Certification

We are conferred the Professional Quality of Securities Investment Consultant Industry by the Securities Association of China and have registered as the Securities Analysts. We hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. We hereby certify that the views expressed in this report accurately reflect our personal views about any or all of the subject securities or issuers referred to herein. We have never been, are not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

### Disclaimer

Industrial Securities Co., Ltd. (hereinafter referred to as the 'Company') is a qualified securities investment consulting institute approved by the China Securities Regulatory Commission.

The report is to be used solely by the clients of the Company. The Company will not treat unauthorized receivers of this report as its clients. The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of research opinions, which are subject to the complete report released on the Company's website (<http://www.xyzq.com.cn>). The clients may ask for follow-up explanations if they so wish.

Based on different assumptions or standards and with different analytical approaches, the Company's salespersons, traders and other professionals may express views, written or oral, towards market trend and securities trading which are inconsistent with opinions and recommendations contained herein. The views in this report are subject to change, and the

### Company has no obligation to update its information with all receivers of the report.

The Company's asset management department, proprietary business department and other investment-related departments may make independent investment decisions based on investment that are inconsistent with opinions and recommendations contained herein.

The report is based on public information; however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any securities. The clients should make investment decisions independently and solely at their own risks.

Under the legal framework, the Company may take positions in and trade stocks of the companies referred to herein, which may receive investment banking services from the Company. The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on the report.

Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report and reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. No one shall have the right to redistribute the report at any circumstances without the prior consent of the Company.

### Global Markets Team

LIU Yirong, Connie	86-21-38,565,452	liuyirong@xyzq.com.cn
ZHANG Zhenlan, Lana	86-21-20,370,633	zhangzhenlan@xyzq.com.cn
XU Hao, Howe	86-21-38,565,450	xuhao@xyzq.com.cn
CHAN Chiwan, Rex	86-21-38,565,439	chanchiwan@xyzq.com.cn

**Important Notice:** This Document may only be issued or passed on to any person in the United Kingdom if that person is of a kind described in Article 19 of the Financial Services and Markets Act 2,000 (Financial Promotions) Order 2,001 or otherwise pursuant to exemptions to section 21 of the Financial Services and Markets Act 2,000. In addition, no person who is an Authorized Person may issue or pass on this document, or otherwise promote SPSE, to any person in the United Kingdom other than by the rules of the Financial Conduct Authority (FCA) applicable to such Authorized Persons. This Document is confidential and is intended solely for the use of its recipient.

**SinoPac Securities (Europe) Limited is regulated by the FCA.** SinoPac Securities (Europe) Limited based in London, act as an agent for SinoPac Securities Corporation in Taiwan for trading in the Taiwan market and SinoPac Securities (Asia) Limited in Hong Kong for trading in the China and Hong Kong markets.

---

**Contact Details:****LONDON**

SinoPac Securities (Europe) Ltd.

4th Floor Mitre House

12-14 Mitre Street

London EC3A 5BU

United Kingdom

Registered in England and Wales No. 3,766,464

Tel: (44 20) 7,614 9,999

Fax: (44 20) 7,614 9,979

Group Email: sinopac@sinopac.co.uk

---

**SinoPac Securities London Team:**

Juno Lee	+44 (0)207 614 9,988	juno.lee@sinopac.co.uk
Andrew Barnie	+44 (0)207 614 9,983	andrew.barnie@sinopac.co.uk
Lily Ho	+44 (0)207 614 9,984	lily.ho@sinopac.co.uk
Changyin Hsu	+44 (0)207 614 9,982	changyin.hsu@sinopac.co.uk
Kahfei Ho	+44 (0)207 614 9,977	kahfei.ho@sinopac.co.uk
Stanley Shu	+44 (0)207 614 9,986	stanley.shu@sinopac.co.uk

---